World journal of surgical oncology · 2026
Clinical association between myelodysplastic syndrome and de novo bone metastasis in urothelial carcinoma.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shen Zhilong Zestel, Xu Gan, Zhang Hao, Wang Pengru, Zhang Xin, Li Bo, Xiao Jianru, Xu Wei
Аннотация
AIM: To assess the association between myelodysplastic syndrome and de novo bone metastasis of urothelial carcinoma.
METHOD: A cohort of 145,719 patients with MDS and/or UTCA included from the surveillance, epidemiology, and end results (SEER) database was conducted to assess the risk of de novo bone metastasis of UTCA (DNBM-UTCA) in patients with previously diagnosed myelodysplastic syndrome (PD-MDS). The odds ratio for developing DNBM-UTCA between MDS and non-MDS patients was estimated. Weibull accelerated failure time model was applied to evaluate the survival outcomes of patients with UTCA.
RESULTS: Our findings suggest that PD-MDS is a powerful risk factor for DNBM-UTCA (adjusted odds ratio, 6.428; 95% CI, 1.866-16.497; p < 0.001) and a poor prognostic factor on survival (adjusted survival time ratio, 0.485; CI, 0.338-0.695; p < 0.001).
CONCLUSION: Our findings suggest that PD-MDS was associated with higher odds of DNBM-UTCA and poorer survival outcomes, which may warrant additional clinical attention during treatment decision-making. However, these findings should be considered hypothesis-generating rather than causal. Further prospective studies and mechanistic investigations are needed to better clarify the biological basis underlying the observed association between PD-MDS and bone metastasis in UTCA.
METHOD: A cohort of 145,719 patients with MDS and/or UTCA included from the surveillance, epidemiology, and end results (SEER) database was conducted to assess the risk of de novo bone metastasis of UTCA (DNBM-UTCA) in patients with previously diagnosed myelodysplastic syndrome (PD-MDS). The odds ratio for developing DNBM-UTCA between MDS and non-MDS patients was estimated. Weibull accelerated failure time model was applied to evaluate the survival outcomes of patients with UTCA.
RESULTS: Our findings suggest that PD-MDS is a powerful risk factor for DNBM-UTCA (adjusted odds ratio, 6.428; 95% CI, 1.866-16.497; p < 0.001) and a poor prognostic factor on survival (adjusted survival time ratio, 0.485; CI, 0.338-0.695; p < 0.001).
CONCLUSION: Our findings suggest that PD-MDS was associated with higher odds of DNBM-UTCA and poorer survival outcomes, which may warrant additional clinical attention during treatment decision-making. However, these findings should be considered hypothesis-generating rather than causal. Further prospective studies and mechanistic investigations are needed to better clarify the biological basis underlying the observed association between PD-MDS and bone metastasis in UTCA.